In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.


This activity focuses on using busulfan to manage and treat allogeneic hematopoietic progenitor cell transplantation, particularly for patients with chronic myelogenous leukemia and other relevant disorders. As an antineoplastic alkylating agent, busulfan is a crucial medication for treating these conditions, which warrants a review of its indications, mechanisms of action, and contraindications. By exploring its pharmacokinetics, dosing regimens, adverse event profile, and clinical toxicology, this program equips participants with the knowledge to optimize busulfan therapy. This activity also discusses the significance of informed prescription practices and tailored dosage strategies to enhance treatment efficacy while minimizing potential adverse effects, thereby improving patient outcomes in managing chronic myelogenous leukemia and related conditions.

Publication types

  • Study Guide